Overview
Thymosin Alpha-1 (Tα1) is a synthetic 28-amino acid immunomodulatory peptide originally isolated from thymosin fraction 5, a bioactive extract derived from thymus tissue. It represents the N-terminal sequence of prothymosin alpha and is used as a laboratory reagent in experimental models investigating immune system regulation, host defense mechanisms, T-cell differentiation, and cytokine-mediated signaling networks.
Published studies include cell-based experiments and in-vivo animal research assessing molecular endpoints such as T-cell receptor signaling, interferon production, dendritic cell maturation, and pathway-level biomarkers under controlled experimental conditions. The cited literature spans rodent models, cell culture systems, and non-human primate studies used to quantify immune-function metrics, viral clearance endpoints, and transcriptional responses following exposure to thymic peptides.
Biochemical Characteristics
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
- Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
- Molecular Weight: 3,108.3 g/mol
- CAS Number: 62304-98-7
- N-Terminal Modification: Acetylated serine (critical for biological activity in research models)
Research Applications
Thymosin Alpha-1 is commonly utilized in experimental research settings focused on the following areas:
Immune Cell Differentiation & T-Cell Biology
Experimental systems measuring T-cell maturation, CD4+/CD8+ differentiation, regulatory T-cell induction, and thymic education endpoints in cell-based and animal models.
Toll-Like Receptor (TLR) Signaling & Innate Immunity
Research evaluating TLR-2, TLR-4, and TLR-9 pathway activation, MyD88-dependent signaling cascades, and NF-κB/AP-1 transcriptional responses in immune cell cultures.
Interferon Production & Antiviral Immunity
Assays quantifying Type I (IFN-α/β) and Type II (IFN-γ) interferon expression, interferon regulatory factor (IRF) activation, and viral clearance mechanisms in controlled infection models.
Dendritic Cell Maturation & Antigen Presentation
Studies assessing dendritic cell phenotype, MHC class II expression, co-stimulatory molecule upregulation (CD80, CD86), and T-cell priming capacity under controlled conditions.
Cytokine Network Regulation
Cell culture and animal model systems evaluating IL-2, IL-12, TNF-α, and IL-6 expression patterns, Th1/Th2 polarization, and cytokine modulation in inflammation research paradigms.
Cancer Immunology Endpoints
Exploratory tumor-bearing rodent models evaluating tumor-infiltrating lymphocyte populations, immune checkpoint interactions, and vaccine adjuvant responses as research outcomes.
Immunosenescence & Thymic Function Research
Aging animal model studies evaluating thymic involution, naive T-cell populations, thymulin secretion, and immune surveillance capacity as experimental measures.
Pathway & Mechanistic Context
Mechanistic work in the cited literature places Thymosin Alpha-1 within several experimentally tractable immunological contexts. Cell-based studies describe TLR-mediated signaling activation and downstream transcriptional responses following peptide exposure, supporting its use as a tool compound in innate immunity research.
Additional studies describe interactions with dendritic cells and T-cell populations as a framework for evaluating immune cell maturation and antigen presentation in cell-culture and ex vivo systems. Common endpoints include surface marker expression, cytokine secretion profiles, transcriptional output at the mRNA and protein level, and pathway-linked molecular markers.
Reported immune, transcriptional, and molecular endpoints associated with Thymosin Alpha-1 in the literature include:
- TLR-2/TLR-9 — innate immune receptor pathway modeling
- MyD88/NF-κB — downstream signaling cascade studies
- IFN-α/β/γ — interferon production and antiviral response targets
- IL-2/IL-12 — T-cell activation and Th1 polarization cytokines
- CD80/CD86 — dendritic cell co-stimulatory molecule endpoints
- MHC-II — antigen presentation capacity markers
- Perforin/Granzyme — NK cell cytotoxicity pathway targets
- Thymulin — thymic function biomarker in aging studies
Preclinical Research Summary
1. T-Cell Development & Thymic Function Endpoints
Preclinical investigations include rodent studies evaluating thymic cellularity, T-cell subset distributions, and thymulin secretion under defined experimental conditions. Cell-based studies describe T-cell receptor signaling and differentiation markers as experimental readouts.
2. Toll-Like Receptor Signaling & Innate Immune Activation
Cell-culture studies describe TLR agonist activity and downstream transcriptional responses as an experimental framework for innate immunity modulation. Studies report NF-κB nuclear translocation and pro-inflammatory cytokine expression as measured molecular endpoints.
3. Interferon Production & Antiviral Defense Mechanisms
The literature includes rodent viral infection models evaluating interferon expression, viral load reduction, and liver enzyme normalization in hepatitis B and C research contexts. Natural killer cell cytotoxicity enhancement has also been reported as an experimental endpoint.
4. Dendritic Cell Maturation & Antigen Presentation
Multiple studies evaluate dendritic cell phenotypic changes, including upregulation of MHC class II and co-stimulatory molecules, following Tα1 exposure. Ex vivo studies assess T-cell priming capacity as a functional research outcome.
5. Cytokine Regulation & Th1/Th2 Balance
Studies describe regulatory effects on cytokine networks involving IL-2, IL-12, IFN-γ, and modulation of Th2 response profiles. Rodent sepsis models report examination of pro-inflammatory cytokine pathway activity including TNF-α and IL-6 as research outcomes.
6. Cancer Immunology & Vaccine Adjuvant Research
Referenced studies include tumor-bearing rodent models assessing tumor-infiltrating lymphocyte populations, delayed tumor progression, and responses to immune checkpoint inhibitors under controlled laboratory conditions. Vaccine studies report antibody titer and cellular immune response endpoints when Tα1 is used as an adjuvant compound.
7. Immunosenescence & Aging Models
Aging animal studies evaluate thymic function markers, naive T-cell population dynamics, and immune surveillance capacity as experimental measures following Tα1 administration in controlled research settings.
Form & Analytical Testing
Thymosin Alpha-1 is supplied as a lyophilized synthetic peptide for controlled laboratory workflows. Peptide identity and analytical attributes are commonly verified using:
- HPLC — purity profiling and lot consistency
- Mass Spectrometry (MS) — molecular identity confirmation
Registry identifiers and structural data including sequence, molecular formula, molecular weight, and CAS number are provided for internal documentation and study design reference.
Purity & Quality
- ≥99% Purity — HPLC Verified
- Independently tested by accredited third-party laboratory
- Certificate of Analysis (CoA) available for every batch
Research Use Only (RUO) Notice
All products are furnished strictly for in-vitro laboratory research use only. "In-vitro" refers to studies conducted outside of a living organism in controlled laboratory conditions. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.
